INTERRELATIONSHIP BETWEEN LIVER FUNCTION, THYROID GLAND FUNCTION, OBESITY AND MICROBIOTA

Kateryna Pivtorak; Oleksandr Ivanchuk; Nataliya Pivtorak; Tetyana Shevchuk

doi:10.36074/grail-of-science.19.09.2025.064

INTERRELATIONSHIP BETWEEN LIVER FUNCTION, THYROID GLAND FUNCTION, OBESITY AND MICROBIOTA

Authors

Kateryna Pivtorak National Pirogov Memorial Medical University, Ukraine https://orcid.org/0000-0001-9187-7964
Oleksandr Ivanchuk National Pirogov Memorial Medical University, Ukraine https://orcid.org/0000-0002-3008-5207
Nataliya Pivtorak National Pirogov Memorial Medical University, Ukraine https://orcid.org/0000-0002-0162-3010
Tetyana Shevchuk National Pirogov Memorial Medical University, Ukraine

DOI:

https://doi.org/10.36074/grail-of-science.19.09.2025.064

Keywords:

MASLD, hypothyroidism, obesity, microbiota, bacterial overgrowth, intestinal permeability, probiotics

Summary

Hypothyroidism affects metabolism and can be an important factor in the development of metabolic disorders. Metabolic-associated fatty liver disease (MASLD) and obesity occupy a special place in clinical practice due to the high risk of progression to cirrhosis and cardiovascular complications. Recent data suggest that intestinal dysbiosis may act as a key mediator in the pathogenesis of these conditions. This article reviews the pathogenetic mechanisms of the interaction of hypothyroidism, MASLD and obesity, as well as the role of microbiota as a potential target for therapeutic intervention, in particular with the help of probiotics and other corrective measures.

Downloads

PDF

Downloads

Download data is not yet available.

License

References

Sbraccia P, Finer N, editors. Obesity. Pathogenesis, Diagnosis, and Treatment. Springer; 2019. Part of the Endocrinology book series (ENDOCR), Cordero P, Li J, Oben JA. Obesity and NAFLD; p. 179-194.

Півторак К.В. Ендотеліальна дисфункція та неалкогольна жирова хвороба печінки. Вінниця: Нова книга;2022.192 с.

Півторак КВ. Антропометричне дослідження хворих на неалкогольну жирову хворобу печінки. Запорожский медицинский журнал. 2017; 19, 5(104): 623-628.

Loomis KA, Kabadi S, Preiss D, Hyde C, Bonato V, St Louis M, et al. Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies. J Clin Endocrinol Metab. 2016 Mar; 101(3): 945-952. doi: 10.1210/jc.2015-3444. DOI: https://doi.org/10.1210/jc.2015-3444

Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017 Jan; 14(1): 32-42. doi: 10.1038/nrgastro.2016.147. DOI: https://doi.org/10.1038/nrgastro.2016.147

Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology. 2016 Oct; 63(1): 138-147. doi: 10.1002/hep.27981. DOI: https://doi.org/10.1002/hep.27981

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul; 64: 73-84. DOI: https://doi.org/10.1002/hep.28431

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012 Sep; 56(3): 943-951. doi: 10.1002/hep.25772. DOI: https://doi.org/10.1002/hep.25772

Півторак КВ. Стан ліпідного, вуглеводного обмінів та функції серцево-судинної системи хворих на неалкогольну жирову хворобу печінки з надлишковою масою тіла та ожирінням. Вісник проблем біології та медицини. 2013; 3, 1(102): 158-161.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015 Aug; 149(2): 389-397. e10. doi: 10.1053/j.gastro.2015.04.043. DOI: https://doi.org/10.1053/j.gastro.2015.04.043

Pivtorak K.V., Shcherbenyuk N.V., Pivtorak N.A., Mazur H.M., Luchenko Ya.V. The role of endothelial dysfunction and insulin resistance in the development of cardiovascular complications in patients with metabolic dysfunction-associated steatotic liver disease. Перспективи та інновації науки 2025; 2(48), 1917-1935. doi.org/10.52058/2786-4952-2025-2(48)-1917-1935 DOI: https://doi.org/10.52058/2786-4952-2025-2(48)-1917-1935

Степанов ЮМ, Филиппова АЮ. Дислипидемия у пациентов с неалкогольным стеатозом печени и билиарной патологией и пути ее коррекции. Сучасна гастроентерологія. 2010; 4(54): 46-51.

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and Cardiovascular Damage in Patients with Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin. Gastroenterol. Hepatol. 2017 Oct; 15(10): 1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. DOI: https://doi.org/10.1016/j.cgh.2017.04.045

Пивторак ЕВ. Нарушения функции эндотелия у больных неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2014; 102(2): 63.

Enjoji, M.; Yasutake, K.; Kohjima, M.; Nakamuta, M. Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol. Int. J. Hepatol. 2012; 2012: 1-6. doi: 10.1155/2012/925807. DOI: https://doi.org/10.1155/2012/925807

Perdomo CM, Frühbeck G, Escalada J. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients. 2019 Mar 21; 11(3): pii: E677.

Safari F, Nabavizadeh A, Vardanjani HM. The association between thyroid function and insulin resistance as measured by the metabolic score for insulin resistance (METS-IR): insights from NHANES 2007-2012. BMC Endocr Disord. 2024;24(1):267. Published 2024 Dec 18. doi:10.1186/s12902-024-01779-y DOI: https://doi.org/10.1186/s12902-024-01779-y

Melnyk, T., & Pivtorak, K. (2024). MICROBIOME AND OBESITY. Grail of Science, (38), 379–389. https://doi.org/10.36074/grail-of-science.12.04.2024.065 DOI: https://doi.org/10.36074/grail-of-science.12.04.2024.065

Pivtorak KV. Features of pharmacotherapy of nonalcoholic fatty liver disease in patients with excess body weight and obesity. Zaporizhzhya Medical Journal. 2017; 19, 4 (103): 520-524. DOI: https://doi.org/10.14739/2310-1210.2017.4.105301

Pivtorak, K.V., Mazur, I.A., & Voloshin, M.A. (2017) Correction of metabolic disorders caused by non-alcoholic fatty liver disease. Deutscher wissenschaftsherold German Science Herald. 4: 74-77.

Ruiz, C.G. & Checa, J.C.F. (2018) Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease. Hepatol Commun. 2(12): 1425-1439. DOI: https://doi.org/10.1002/hep4.1271

Pivtorak KV, Shevchuk NA, Pivtorak NA, Fedzhaga IV. Correction of adipocyte secretion disorders in patients with non-alcoholic fatty liver disease with overweight and obesity. Wiad Lek. 2019 Aug 31;72(8):1477-1480. DOI: https://doi.org/10.36740/WLek201908111

Perdomo, C. M., Frühbeck, G., & Escalada, J. (2019). Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients, 11(3), 677. DOI: https://doi.org/10.3390/nu11030677

Pivtorak K, Yakovleva O, Pivtorak N, Fedzhaga I, Doroshkevich I. Metabolic features of adipose tissue and clinical significance of adipokins in patients with non-alcoholic fatty liver disease (review). Georgian Medical News 2021. 7-8 (316-317), 135-141.

Pivtorak, K.V., Marchuk O.V. (2022). Nonalcoholic fatty liver disease and sarcopenia. Bulletin of problems of biology and medicine. 3(166): 79-86. DOI: https://doi.org/10.29254/2077-4214-2022-3-166-79-86

Pivtorak K, Monastyrskyi V, Kuleshov O, Fedzhaga I, Pivtorak N. Relationship between sarcopenia and osteoporosis in non-alcoholic fatty liver disease. Georgian Med News. 2022 May;(326):12-17.

Pivtorak KV. Peculiarities of the cell cycle of hepatocytes in experimental nonalcoholic fatty liver disease and its correction. Bulletin of Problems of Biology and Medicine. 2017; 1 (135): 170-174.

Pivtorak K, Fedzhaga I, Pivtorak N, Shevchuk N. Role of systemic inflammation and atherogenesis in the development of NAFLD and concomitant cardiovascular diseases. Atherosclerosis 2021 331, e232-e233. DOI: https://doi.org/10.1016/j.atherosclerosis.2021.06.715

Skrypnyk I.M., Shcherbak O.V., Maslova G.S. Influence of non-alcoholic steatohepatitis on the course and progression of coronary heart disease. Wiadomości Lekarskie. April 20, 2017; 70(2): 236-40. (in Ukrainian)

Serhiyenko, V., & Serhiyenko, A. (2022). Diabetes mellitus and congestive heart failure. International journal of endocrinology (Ukraine), 18(1), 57–69. https://doi.org/10.22141/2224-0721.18.1.2022.1146 DOI: https://doi.org/10.22141/2224-0721.18.1.2022.1146

Khukhlina O.S., Antoniv A.A., Mandryk O.Y., Smandych V.S., Matushchak M.R. The role of endothelial dysfunction in the mechanisms of progression of non-alcoholic stepage hepatitis in patients with obesity and chronic kidney disease. Viad Leck. 2019; 72(4): 523-526. DOI: https://doi.org/10.36740/WLek201904103

Cherniavskyi V. V., Didyk O. K. Study of fatty acid-binding protein and Bacteroidetes and Firmicutes levels in patients with metabolic-associated fatty liver disease in combination with type 2 diabetes mellitus and small intestinal bacterial overgrowth syndrome. Zaporizhzhia Medical Journal, 2024;26(2):114-117. https://doi.org/10.14739/2310-1210.2024.2.296120 DOI: https://doi.org/10.14739/2310-1210.2024.2.296120